In most of these markets, the Commission found that the overlapping activities of the parties were unlikely to lead to adverse competition effects. However, serious doubts arose in a number of key areas where the new entity would have achieved very high market shares, up to almost 100%, in three markets: anti-virals, excluding anti-HIV (J5B), topical anti-virals (D6D) and anti-emetics (A4A).
Auf drei wichtigen Märkten wären die Parteien jedoch auf einen Anteil von fast 100% gekommen: antivirale Substanzen mit Ausnahme von Aids-Mitteln (J5B), örtliche Viruzide (D6D) und Antiemetika (A4A).